Detailed explanation of the usage of F/TAF PrEP and analysis of correct taking methods and precautions

1. Basic introduction to Dakohui (F/TAF)

F/TAF, full name Emtricitabine/Tenofovir Alafenamide Fumarate, brand name Descovy) is a compound preparation containing two antiviral ingredients, mainly used to prevent and treat HIV infection. InPrEP (pre-exposure prophylaxis, Pre-Exposure Prophylaxis), F/TAF is currently another PrEP medication regimen approved by FDA besides TDF/FTC (commonly known as "blue tablet"). It inhibits HIV's reverse transcriptase activity and prevents the virus from replicating in the body, thus significantly reducing the risk of infection. Compared with traditional TDF/FTC, F/TAF is safer in terms of bone density and renal function, and is especially suitable for high-risk groups with osteoporosis or mildly abnormal renal function. However, the current indications for F/TAF PrEP are limited to men who have sex with men (MSM) and transgender women, and are not suitable for women who have vaginal sex. This is due to insufficient relevant clinical trial data.

2. F/TAF PrEPStandard taking method

The standard use of F/TAF PrEP is to take one tablet daily, with a fixed dose that does not need to be adjusted based on body weight. It is recommended to take it at a fixed time every day to ensure stable drug concentration in the body. Although it can be taken with or without food, taking it after a meal may help reduce some gastrointestinal discomfort. F/TAFThe pharmacokinetic characteristics of F/TAF in the body enable it to maintain high concentrations in the blood and lymphatic system. Therefore, regular daily consumption is the key to achieving maximum preventive effect.

Before starting to take medication, an HIV test is required to ensure that the person taking the medication is not infected with the HIV virus. In addition, renal function, hepatitis B status, and other sexually transmitted diseases need to be evaluated. While taking F/TAF as PrEP, it is recommended to take HIV once every 3 monthsTest, and regularly check kidney function, liver function and necessary STD screening. If medication is interrupted, once you restart taking it, you need to take it continuously for at least 7 days to reach the effective preventive concentration.

3. Precautions and safety monitoring

F/TAFAlthough safety is relatively high, potential side effects and drug interactions still need to be noted. Common adverse reactions include mild nausea, diarrhea, fatigue and headache, which generally diminish over time. Individual patients may experience elevated liver enzymes or slight changes in renal function, so it is recommended to review regularly as directed by your doctor. For patients with hepatitis B infection, F/TAF also has an anti-hepatitis B virus effect, but if the drug is stopped suddenly, the hepatitis B virus may rebound. Therefore, such patients should be closely monitored under the guidance of a doctor when stopping the drug.

In terms of drug interactions, care should be taken to avoid simultaneous use with certain antiepileptic drugs (such as carbamazepine), antifungal drugs (such as ketoconazole), rifampin drugs, and certain antiarrhythmic drugs. These drugs may affect the concentration of F/TAF in the body. If you need to use other drugs while taking this medicine, you should consult your doctor or pharmacist to ensure that no adverse interactions will occur.

4. Special groups and clinical use recommendations

F/TAFPrEP is not recommended for vaginal intercourse in women due to insufficient clinical protection data. In actual use, men who have sex with men and transgender women are currently the main users. For high-risk groups with mildly reduced renal function or bone density problems, F/TAF has obvious advantages over TDF/FTC and can be a preferred choice.

In addition, for PrEP people who require high compliance, the once-daily dosing regimen of F/TAF is simple and convenient, helping to improve medication adherence. If there is a high-risk exposure to HIV infection while taking medication (such as condom breakage or needle sharing), comprehensive protection should be carried out in conjunction with the PEP (post-exposure prophylaxis) strategy. If the HIV test is positive while PrEP is being taken, PrEP should be stopped immediately and switched to standard antiviral treatment to avoid the risk of drug resistance.

Dakova (F/TAF) as a new generationPrEPMedication has better kidney and bone safety and is suitable for long-term use by specific groups of people. The correct way to take the medicine is to take one tablet orally every day, and strictly follow the testing and follow-up procedures to ensure the preventive effect and safety. In actual application, it is necessary to choose whether F/TAF PrEP is suitable based on personal exposure risk, health status and behavioral patterns, combined with doctor's guidance. For high-risk groups, taking medication regularly and reviewing on time are key steps to prevent HIV infection.

Reference materials:https://www.drugs.com/